• Explore /
  • Poster
  • / FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

Abstract Poster

Authors

null

Vincent Picozzi

Digestive Diseases and Cancer Institutes, Virginia

Vincent Picozzi , J. Pipas , Albert Koong , Amato Giaccia , Nathan Bahary , Smitha Krishnamurthi , Charles Lopez , Peter O'Dwyer , Katharina Modelska , Vanessa Poolman , James Chou , Ming Zhong , Seth Porter , Tom Neff , Frank Valone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01181245

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr213)

DOI

10.1200/jco.2013.31.4_suppl.213

Abstract #

213

Poster Bd #

B17

Abstract Disclosures

Similar Posters

First Author: Vincent J. Picozzi

First Author: Vincent J. Picozzi

Poster

2020 Gastrointestinal Cancers Symposium

Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.

Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.

First Author: Mark D. Sternlicht

First Author: Vincent J. Picozzi